Repurposing existing candidates to allow administration via a different route such as inhaled or nasal can be a viable strategic route to get the products to patients faster, however, many candidates are not yet in a format suitable for delivery to the lungs. Inhaled administration offers significant repurposing opportunities for both local and systemic therapeutic delivery and vaccines. Redevelopment must be fast, effective and accurate with tight control over quality in order to get a drug ready for clinical trials.  

In this webinar, Mark Parry, Technical Director, Intertek Melbourn, describes the strategies required for rapid repurposing for inhaled delivery, discussing considerations whilst mitigating anticipated challenges. 

Please complete the form to listen to the webinar.